Invitation to R&D Update of Molecular Partners AG on the DARPin(R) Difference - Offering Patients a New Dimension of Protein Therapeutics
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / September 19, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs known as DARPin® therapies, is hosting an R&D update on "The DARPin® Difference - Offering Patients a New Dimension of Protein Therapeutics." The event takes place in New York on November 9, 2017, 12.00-2.30 pm EDT. The meeting will feature a presentation by C....
Read more









